Abstract: The aminoglycoside modifying enzyme (AME) ANT(2 00 )-Ia is a significant target for next generation antibiotic development. Structural studies of a related aminoglycoside-modifying enzyme, ANT(3 00 )(9), revealed this enzyme contains dynamic, disordered, and well-defined segments that modulate thermodynamically before and after antibiotic binding. Characterizing these structural dynamics is critical for in situ screening, design, and development of contemporary antibiotics that can be implemented in a clinical setting to treat potentially lethal, antibiotic resistant, human infections. Here, the first NMR structural ensembles of ANT(2 00 )-Ia are presented, and suggest that ATP-aminoglycoside binding repositions the nucleotidyltransferase (NT) and C-terminal domains for catalysis to efficiently occur. Residues involved in ligand recognition were assessed by site-directed mutagenesis. In vitro activity assays indicate a critical role for I129 toward aminoglycoside modification in addition to known catalytic D44, D46, and D48 residues. These observations support previous claims that ANT aminoglycoside sub-class promiscuity is not solely due to binding cleft size, or inherent partial disorder, but can be controlled by ligand modulation on distinct dynamic and thermodynamic properties of ANTs under cellular conditions. Hydrophobic interactions in the substrate binding cleft, as well as solution dynamics in the C-terminal tail of ANT(2 00 )-Ia, advocate toward design of kanamycin-derived cationic lipid aminoglycoside analogs, some of which have already shown antimicrobial activity in vivo against kanamycin and gentamicin-resistant P. aeruginosa. This data will drive additional in silico, next generation antibiotic development for future human use to combat increasingly prevalent antimicrobial resistance.
Introduction
A half-century of mass antibiotic use has seen an emergence in resistant clinical isolates. The aminoglycoside class of antibiotics remaining in clinical use today include gentamicin, tobramycin, dibekacin, and sisomicin, with gentamicin being the most frequently administered in the emergency department. 1 Gentamicin is used to treat ventilatorassociated pneumonia common with cystic fibrosis or traumatic burns (Pseudomonas aeruginosa), wound infections (Pseudomonas aeruginosa, Proteus mirabilis), bacterial broncopneumonia (Klebsiella pneumoniae), urinary tract infections (E. coli, Enterobacter spp.), and catheter-associated bacteremia (Serratia spp.). Bacteria can alter active transport, accumulate changes to the ribosome, express modifying enzymes, or any combination thereof, to deter to the lethal effects of aminoglycoside antibiotics. 2 This process is known as developing aminoglycoside antibiotic resistance. Aminoglycoside resistance outside of nosocomial (hospital acquired) infections remains limited, but has been reported for strains of Pseudomonas aeruginosa, Enterobacteriaceae, E. coli, Serratia spp., and Staphylococcus aureus. 1 Resistance decreases treatment success, lengthens hospital stay, and less frequently, ends in mortality (21 vs 12%). 3 Targeting bacterial expression of aminoglycoside modifying enzymes (AMEs) with next generation antibiotics resistant to modification as well as AME inhibitors, is pharmacologically attractive because the majority of resistance is caused by AME activity, 4 and this high-level AME resistance leads to difficulties treating clinical illnesses. AMEs carry out enzymatic inactivation of aminoglycosides by three mechanisms: acetylation (AACs), nucleotidylation (ANTs), and phosphorylation (APHs). 5 Aminoglycoside O-nucleotidyltransferases (ANTs) bind ATP coordinated with magnesium followed by aminoglycoside, adenylate a specific hydroxyl group of the aminoglycoside substrate, then release modifiedaminoglycoside and inorganic phosphate to complete the inactivation reaction 6 . Aminoglycoside resistance mediated by nucleotidyltransferase ANT(2 00 )-Ia is world-wide, with reported clinical prevalences of 4% (Japan), 7 12.9% (Nigeria), 8 27% (USA), 7 27.6% (Spain), 9 and 78.87% (Iran). 10 The X-ray crystallographic structure of ANT(2 00 )-Ia has been previously determined. 11, 12 However, X-ray, SAXS, and ITC structural studies of ANT(3 00 )(9) (56.4% similarity with ANT(2 00 )-Ia 13 ), reveal ANTs are dynamic, contain disordered segments, and aminoglycoside binding modulates the active site, shifting the thermodynamic properties of these enzymes. 14 Our NMR studies of ANT(2 00 )-Ia corroborate such findings of solution protein dynamics, with ATP-aminoglycoside binding stabilizing nucleotidyltransferase (NT) domain and C-terminal domain interactions for aminoglycoside nucleotidylation to efficiently proceed. Together, these new structural findings will be invaluable for competent in silico next generation antibiotic design, and development of novel drugs to resensitize multi-drug resistant microorganisms.
Efforts now center around developing semisynthetic aminoglycosides averse to enzymatic inactivation, as well as direct, AME inhibitors. Protein structural information has already proven invaluable to AME inhibitor screening and identification. 15 These contemporary NMR structural studies of adenyltransferase ANT ( (Fig. 2) , and were used in subsequent side-chain, NOE (Supporting Information Fig. S1 ), structural, and titration analyses. C-NOESY ANT(2 00 )-Ia experiments collected in 10% and 100% D 2 O revealed rearrangements in apo ANT(2 00 )-Ia a4-a6 helices short, medium, and long range NOE hydrogen interactions. It is worth mentioning NOESY experiments of ANT(2 00 )-Ia in water (90% H2O/10% D2O) provided discernible, but weak, cross peaks for hydrogen interactions between a4 (Y135), a5 (V139), a6 (H148), and a7 (L159) residues (Table I ). This confirmed a4-a6, closed conformation synergy, as well as a6-long-range, open conformation-solvent interactions for this semi-flexible region. In vitro functional studies of protein mutants
Alanine mutagenesis was performed to monitor in vitro ANT(2 00 )-Ia aminoglycoside modification over time, as well as corroborate NMR observations. D44A, I129A, Y135A protein mutations were purified [Supporting Information Fig. S2(A) ] and analyzed by 1D 1 H-NMR [Supporting Information Fig. S2(B) ]. Sharp, well separated peaks in the amide/aromatic and aliphatic regions for all verified each protein mutation was well-folded, and any observed changes in activity were not due to mutation-induced misfolding or aggregation. Unexpectedly, highly conserved Y135A only caused a minor 1.6-fold decrease in aminoglycoside adenylation [ Fig. 4(A) ]. However, aminoglycoside modification diminished 3-fold for nearby I129A, suggesting this amino acid substitution hinders C-terminal conformation dynamics, substrate recognition, or both. D44A caused a 4-fold decrease in aminoglycoside modification as expected [ Fig. 4(A) ]. Based on NMR and mutagenesis experiments, we propose a 
Solution structure catalytic residues
Previously solved X-ray crystal structures of ANT(2 00 )-Ia bound with AMP-tobramycin (PDB ID: 5CFS) and adenylated tobramycin (PDB ID: 5CFU) indicated key residues involved in ATP binding and aminoglycoside modification catalysis [ Fig. 5(A) ]. 12 The NMR solution conformers of ANT(2 00 )-Ia (PDB ID: 5KQJ) propose Y74, Y134, and Y135 hydrophobic stacking interactions cooperate to coordinate aminoglycoside binding recognition [ Fig. 5(B,C)] . Additionally, open-closed conformation dynamics modulate K147, H148 ionic interactions with the b-g phosphate moiety of ATP, involved in release of inorganic phosphate after aminoglycoside adenylation. N-HSQC perturbation results for catalytic residues resolved by X-ray crystallography 11, 12 or protein mutagenesis, were further examined. D44, D86, E88, I129, K147, and H148 showed significant titration effects as a results of ATP binding, while D44, Y74, E88, I129, Y134, and K147 considerably shifted from aminoglycoside interactions; D43, D44, Y74, D86, E88, and K147 varied extensively concordant with adenylation catalysis (Fig. 6 ).
Backbone dynamics of ANT(2 00 )-ia ATP-aminoglycoside binding
Analysis of the heteronuclear { 1 H}- 15 N NOE ratio between ANT(2 00 )-Ia bound and unbound to ATP plus tobramycin is a direct method to assess conformational changes promoted due to ligand interactions. Observational changes suggest that while the majority of ANT(2 00 )-Ia is a rigid structure, semiflexible dynamics are observed for ATP-site residues D43 and D46, aminoglycoside modification residues R54, R67, G75, aminoglycoside-recognition residues W125; I129-D137, and C-terminal residues Y152-H185 [ Fig. 7(A) ]. Noticeably increasing semiflexibility in the C-terminus accounted for most backbone dynamics, with strong cross-peaks attributable to tobramycin [ Fig. 7(B) ] and ATP [ Fig. 7(C) ] coordination in respective regions.
Discussion
Overall, our NMR results strongly suggest the existence of closed and open conformational states for ligand-free ANT(2 00 )-Ia in a 7:3 ratio, with ligand-binding shifting this equilibrium to an entirely closed conformation. Analysis of NOE measurements determined and assigned by PONDEROSA-C/S allowed NMR data interpretation augmented by existing crystal structures (PDB ID: 4WQK, 4WQL, 5CFU, 5CFS, 4XJE). 11, 12 PONDEROSA-C/S avoids the underestimated problems associated with maximum-entropy and large-weight approaches of ensemble construction. 20, 21 The 30% population of the open conformation in apo ANT(2 00 )-Ia suggests that solution ligand binding involves what is known as a conformation-selection mechanism, which facilitates ligand binding, and modulation of binding affinity. 22 Rapidly progressing spectroscopic and computational techniques have the possibility to further integrate the study of protein dynamics in solution at an atomic level. Here, we use NMR experimentation and the computational power of PONDEROSA-C/S to reliably interpret structural NOE data, and resolve the conformational dynamics crucial to solution protein interactions, ligand recognition, and binding affinity. inhibitors 15 and design next generation antibiotics, future endeavors will require the most accurate and encompassing structural information for the implementation of both to combat human disease. Here, the NMR solution structure of ANT(2 00 )-Ia offers insight into the repositioning of its NT and C-terminal domains, just as observed for ANT(3 00 )(9)'s NT and Cterminal a-bundle domain, for aminoglycoside binding in the interdomain cleft and catalysis to occur. 14 Both findings are consistent with the regulatory function reported for the C-terminus in proteobacterial members of the polb nucleotidyltransferase superfamily (i.e., CyaA adenylyl cyclase, DNA polymerase k), of which nucleotidyltransferases are a member. 24, 25 ANT(2 00 )-Ia confers resistance by adenylating the 2 00 -OH group of 4,6-disubstituted 2-deoxystreptamines, such as tobramycin, gentamicin, and kanamycin 26 [ Fig. 8(A-C) ]. Kanamycin A-derived cationic lipid compound 15 [ Fig. 8(D) ] was previously shown to restore antibacterial activity against kanamycin and gentamicin-resistant P. aeruginosa. 16 ANT(2 00 )-Ia NMR solution structure conformers advocate development of 4,6-disubstituted 2-deoxystreptamines cationic compounds with lipid or hydrophobic R 2 groups to combat clinical aminoglycoside resistance. Although the exact mechanism of resistance to modification for compound 15 warrants further study, next generation aminoglycosides effective against AMEs are only attractive if these analogs retain ability to inhibit their target (ie. the bacterial ribosome), as well as avoid AME modification. For this purpose, we propose that Kanamycin A-derived cationic compounds (KCCs) that have similar hydrophobic R 2 groups, could target ANT hydrophobic stacking interactions (Y74, Y134), and be effective next generation antibiotics in vivo against gentamicin and kanamycin-resistant microorganisms. 16 Highly static, superimposable X-ray crystal structures of ANT(2 00 )-Ia, while extremely valuable, fail to fully explain protein dynamics according to differential substrate profiles, NMR spectra, H/D exchange data, point mutations (ANT(2 00 )-Ia I129A), and k cat values. 11, 12, [27] [28] [29] [30] Incorporating NMR structural data suggest that ANT aminoglycoside promiscuity is driven by an inherent ANT flexibility largely unpredictable by primary sequence alone. In conclusion, thermodynamic parameters of enzymeligand complexes, NMR conformational dynamics, and protein behavior in solution can complement Xray crystallographic protein structure determination to improve in silico docking algorithms used in the initial steps of identifying next generation antibiotics, as well as compounds to inhibit AMEs. These advancements will lead to the design of new, novel antibiotics, as well as more effective inhibitors to combat clinical antimicrobial resistance. 32 and analyzed in Excel. Error, rigid, semi-flexible, and flexible values were estimated as previously described.
Materials and Methods

Isotopically
33
Data processing and structure determination NMR data were processed with NMRPipe. 31 Backbone and side-chain chemical shifts were assigned manually using SPARKY. 32 15 N-NOESY/ 13 C-NOESY NOE assignments and XPLOR-NIH structural calculations were conducted automatically through the PONDEROSA-C/ S client. 21, 22, 34, 35 KobaMIN was used for final refinement of XPLOR-NIH generated structures. 36 The best models determined by MolProbity were used as the final structures of ANT(2 00 )-Ia. 37, 38 The fifteen best NMR solution structures of ANT(2 00 )-Ia were deposited into the biological magnetic resonance and protein data bank as BMRB ID: 30133 and PDB ID: 5KQJ.
ANT(2 00 )-ia solvent dynamics
Ten percent and 100% D 2 O aliphatic and aromatic 13 C-NOESY spectra were collected on 13 C/ 15 N -ANT(2 00 )-Ia to assess solvent-protein and intermolecular proteinprotein short-, medium-, and long-range NOE interactions.
Protein mutagenesis
pET-22b(1) ANT(2 00 )-Ia D44A, I129A, and Y135A were cloned by overlap extension PCR using appropriate with no substrate, 0.6 mM tobramycin, 0.6 mM ATP, or 0.6 mM tobramycin and 0.6 mM ATP at 258C for one hour with a sample dilution < 10%. 15 N-HSQC spectra were collected using a Bruker DRX 600 MHz NMR spectrometer at 298 K over 3 hours. Data were processed using NMRPipe and analyzed by SPARKY. Chemical-shift perturbation effects were calculated as previously described. 19 
